Skip to main content
. 2023 Dec 5;6(5):677–688. doi: 10.1016/j.cjco.2023.11.024

Figure 1.

Figure 1

Study selection for comparison of (A) ticagrelor vs prasugrel, and (B) purinergic receptor type Y, subtype 12 (P2Y12) inhibitor de-escalation vs continuation of potent P2Y12 inhibitor.